Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of CVT-301 vs Oral Carbidopa/Levodopa in Fed PD Patients
NCT03887884Phase 1Completed
- Sponsor
- Acorda Therapeutics
- Start
- Mar 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of levodopa inhalation powder in Parkinson's disease (PD) (2 arms), sponsored by Acorda Therapeutics. Primary endpoints: Maximum plasma concentration at 4 days, Total plasma concentration at 4 days and 2 more. Started Mar 2019; status: completed.
02
Drugs
levodopa inhalation powder
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03887884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03887884.